Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Commercial prospects for genomic sequencing technologies

Nature Reviews Drug Discovery volume 12, pages 341–342 (2013)Cite this article

Subjects

Key manufacturers and GS technologies

In recent years, there has been an increasing fragmentation of the GS technologies market as several competing manufacturers launched NGS platforms. The leading manufacturers have been strengthening their position through acquisitions, not all of which are in the sequencing domain. For example, Illumina and Life Technologies took considerable steps to enter the genomics-based diagnostics market; Illumina with its acquisition of BlueGnome and Verinata, and Life Technologies' with its purchase of Navigenics. These transactions illustrate the inevitable shift in the application of genomics from a science largely of research value to one poised to be at the heart of medical diagnostics.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Genomic sequencing technologies market: projected revenues (billions of US$) 2012–2017.

References

  1. Visiongain. Genomic sequencing technologies for medicine: market prospects 2011–2021. Visiongain (2011).

  2. Shendure, J. & Lieberman Aiden, E. The expanding scope of DNA sequencing. Nature Biotech. 30, 1084–1094 (2012).

    Article  CAS  Google Scholar 

  3. Norman, T. et al. The precompetitive space: time to move the yardsticks. Sci. Transl. Med. 3, 76cm10 (2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sharmarke Mohamed, Ph.D., and Basharut A. Syed, Ph.D., are at Visiongain, BSG House, 230 City Road, London EC1V 2QY, UK.,

    Sharmarke Mohamed & Basharut A. Syed

Authors
  1. Sharmarke Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Basharut A. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basharut A. Syed.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mohamed, S., Syed, B. Commercial prospects for genomic sequencing technologies. Nat Rev Drug Discov 12, 341–342 (2013). https://doi.org/10.1038/nrd4006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4006

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research